YMAB vs. HRTX, AUPH, AMRN, MRSN, GBIO, PTGX, DCPH, BHC, CPRX, and RXRX
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Heron Therapeutics (HRTX), Aurinia Pharmaceuticals (AUPH), Amarin (AMRN), Mersana Therapeutics (MRSN), Generation Bio (GBIO), Protagonist Therapeutics (PTGX), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "medical" sector.
Heron Therapeutics (NASDAQ:HRTX) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
In the previous week, Heron Therapeutics and Heron Therapeutics both had 4 articles in the media. Heron Therapeutics' average media sentiment score of 0.75 beat Y-mAbs Therapeutics' score of 0.23 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media.
Heron Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 96.72%. Y-mAbs Therapeutics has a consensus price target of $17.86, suggesting a potential upside of 42.52%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than Y-mAbs Therapeutics.
Y-mAbs Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 6.4% of Heron Therapeutics shares are owned by company insiders. Comparatively, 21.5% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Y-mAbs Therapeutics has a net margin of -25.64% compared to Y-mAbs Therapeutics' net margin of -61.28%. Y-mAbs Therapeutics' return on equity of 0.00% beat Heron Therapeutics' return on equity.
Heron Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Heron Therapeutics received 538 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 69.05% of users gave Heron Therapeutics an outperform vote while only 60.91% of users gave Y-mAbs Therapeutics an outperform vote.
Summary
Heron Therapeutics beats Y-mAbs Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
